<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.111005</article-id><article-id pub-id-type="publisher-id">ACM-39683</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210100000_88712933.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  男性乳腺包裹性乳头状癌3例报道并文献复习
  Encapsulated Papillary Carcinoma of the Male Breast: Three Case Reports and Review of the Literature
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>凯迪</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>文凤</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院乳腺病诊疗中心，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>01</month><year>2021</year></pub-date><volume>11</volume><issue>01</issue><fpage>34</fpage><lpage>37</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：乳腺包裹性乳头状癌(Encapsulated papillary carcinoma, EPC)在男性中极为罕见，对其诊断和治疗了解较少。通过探讨3例男性EPC患者的诊断、治疗及预后，旨在为该疾病的规范诊治提供参考。方法：采用病例报道的方式，结合国内外文献，分析3例患者的诊断、治疗及预后。结果：3例男性患者均经乳房肿块切除活检确诊后行手术治疗，术后均行内分泌治疗，随访23~99个月，无复发及转移。结论：男性乳腺EPC是一种极为少见的低度恶性肿瘤，术前诊断仍依赖乳房肿块切除活检，治疗原则可参照女性，以手术治疗为主，预后较好。
    Objective: Encapsulated papillary breast carcinoma is extremely rare in males and its diagnosis and treatment are poorly understood. The diagnosis, treatment and prognosis of 3 male EPC patients were discussed in order to provide reference for the standard diagnosis and treatment of this disease. Methods: The diagnosis, treatment and prognosis of 3 patients were analyzed in the form of case reports and combined with review of foreign literature. Results: All the 3 male patients received surgical treatment after the diagnosis of lumpectomy and biopsy, and received endocrine therapy after the operation. The patients were followed up for 23~99 months without recurrence or metastasis. Conclusion: Male breast EPC is a rare low-grade malignant tumor, preoperative diagnosis still depends on lumpectomy and biopsy, and the treatment principle can be referred to women. Surgical treatment is the main treatment with a favorable prognosis. 
  
 
</p></abstract><kwd-group><kwd>男性，乳腺癌，包裹性乳头状癌，诊断，治疗, Male</kwd><kwd> Breast Cancer</kwd><kwd> Encapsulated Papillary Carcinoma</kwd><kwd> Diagnosis</kwd><kwd> Treatment</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：乳腺包裹性乳头状癌(Encapsulated papillary carcinoma, EPC)在男性中极为罕见，对其诊断和治疗了解较少。通过探讨3例男性EPC患者的诊断、治疗及预后，旨在为该疾病的规范诊治提供参考。方法：采用病例报道的方式，结合国内外文献，分析3例患者的诊断、治疗及预后。结果：3例男性患者均经乳房肿块切除活检确诊后行手术治疗，术后均行内分泌治疗，随访23~99个月，无复发及转移。结论：男性乳腺EPC是一种极为少见的低度恶性肿瘤，术前诊断仍依赖乳房肿块切除活检，治疗原则可参照女性，以手术治疗为主，预后较好。</p></sec><sec id="s2"><title>关键词</title><p>男性，乳腺癌，包裹性乳头状癌，诊断，治疗</p></sec><sec id="s3"><title>Encapsulated Papillary Carcinoma of the Male Breast: Three Case Reports and Review of the Literature</title><p>Kaidi Li<sup>*</sup>, Wenfeng Li<sup>#</sup></p><p>Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/5-1571822x5_hanspub.png" /></p><p>Received: Dec. 6<sup>th</sup>, 2020; accepted: Dec. 19<sup>th</sup>, 2020; published: Jan. 8<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/5-1571822x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Encapsulated papillary breast carcinoma is extremely rare in males and its diagnosis and treatment are poorly understood. The diagnosis, treatment and prognosis of 3 male EPC patients were discussed in order to provide reference for the standard diagnosis and treatment of this disease. Methods: The diagnosis, treatment and prognosis of 3 patients were analyzed in the form of case reports and combined with review of foreign literature. Results: All the 3 male patients received surgical treatment after the diagnosis of lumpectomy and biopsy, and received endocrine therapy after the operation. The patients were followed up for 23~99 months without recurrence or metastasis. Conclusion: Male breast EPC is a rare low-grade malignant tumor, preoperative diagnosis still depends on lumpectomy and biopsy, and the treatment principle can be referred to women. Surgical treatment is the main treatment with a favorable prognosis.</p><p>Keywords:Male, Breast Cancer, Encapsulated Papillary Carcinoma, Diagnosis, Treatment</p><disp-formula id="hanspub.39683-formula12"><graphic xlink:href="//html.hanspub.org/file/5-1571822x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1571822x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-1571822x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>乳腺包裹性乳头状癌是临床上发病率较低的恶性肿瘤，在全部乳腺癌中所占比例不足2% [<xref ref-type="bibr" rid="hanspub.39683-ref1">1</xref>]，主要影响绝经后女性。男性乳腺癌约占所有乳腺癌的1% [<xref ref-type="bibr" rid="hanspub.39683-ref2">2</xref>]，男性EPC患者更为少见，仅在少量的文献中被报道，目前对于其临床特征、治疗和预后尚认识不足。本文回顾性分析3例男性EPC患者的临床资料，并结合文献复习，以加强临床医师对该类疾病的认识，丰富其管理方式。</p></sec><sec id="s6"><title>2. 病例资料</title><p>病例1：53岁男性，因发现右乳肿物10余天入院。查体：右乳头外上方可触及一枚肿块，大小约1.0 &#215; 1.0 cm，质硬，边界清晰，活动度一般，无压痛，乳头无溢液。双侧腋窝下、双侧锁骨上下均未触及肿大淋巴结。彩色多普勒超声示右乳头外上方见一1.1 &#215; 0.8 cm囊性回声，后壁较厚，透声可，未见明显血流信号。曾于外院行右乳肿物穿刺，病理示少量导管上皮细胞，核大深染，有异型，核形不规则，可疑为恶性。完善检查，未见远处转移。于全麻下行右乳肿物切除活检+右乳单纯切除+前哨淋巴结活检+腋窝淋巴结清扫术，术后病理：(右乳肿物)乳头状肿瘤，意见为包裹性乳头状癌(镜下最大径约0.5 cm) (图1(a))，周边见导管原位癌。前哨淋巴结和腋窝淋巴结内均未见癌转移。免疫组化：ER(+++) 90%，PR(+++) 90%，Her-2(−)，CK5/6(−)，CK14(−)，Ki-67阳性率约10%，P53(−)，P63及SMMHC示肌上皮部分缺失，AR(+++) 90%，Topo2(I级)，E-Cadherin(+)，P120 Catenin膜(+)。术后口服托瑞米芬治疗，随访23个月，未见复发和转移。</p><p>病例2：56岁男性，因发现左乳肿块10余年，左乳头溢液10余天入院。查体：左侧乳房乳晕下可触及一枚肿块，大小约1.0 &#215; 1.0 cm，左侧乳头挤压见少量溢液，无色透明，质澄清。右乳未见异常。双侧腋窝下、双侧锁骨上下均未触及肿大淋巴结。彩色多普勒超声示左乳11点乳头旁探及1.4 &#215; 0.7 cm低回声结节，形态欠规则，边界清，内回声欠均匀，CDFI：内未见明显血流信号。右乳未见明确实性结节。双侧腋下、颈部未见异常肿大淋巴结。在我院局麻下行左乳肿物穿刺活检，病理提示乳头状肿瘤，生长活跃，建议术中冰冻协助诊断。遂行乳房肿块切除术，术后病理：(左乳肿物)乳腺乳头状肿瘤(图1(b))，结合免疫组化结果及镜下形态，符合包裹性乳头状癌(直径1 cm)，周围脂肪淋巴管内见癌栓。免疫组化：ER(+++) 80%，Her-2(−)，CK5/6(−)，P63(−)，SMHHC(−)，Ki-67阳性率10%，CerbB-2(1+)。后行左侧乳房单纯切除 + 前哨淋巴结活检术，术中病理：切缘均阴性，前哨淋巴结内未见癌转移。术后口服他莫昔芬治疗，随访57个月，无复发和远处转移。</p><p>病例3：73岁男性，因发现左乳肿块半年入院。查体：左乳头下方可触及一枚肿物，大小约3.0 &#215; 3.0 cm，质硬，界清，未累及皮肤及胸壁，腋窝未触及肿大淋巴结。彩色多普勒超声示左乳头下方见一3.0 &#215; 2.4 cm囊实性包块。于全麻下行左乳肿物切除活检 + 左乳癌改良根治术，术后病理：(左)乳腺导管内乳头状癌，考虑为包裹性乳头状癌(直径1.5 cm) (图1)，伴少部分浸润性癌，间质脉管内未见癌栓形成。切缘均阴性，腋窝淋巴结内未见癌转移。免疫组织化学检测：ER(++) 80%，PR(+++) 80%，HER-2(−)，CK5/6(−)，CK14(−)，Ki-67阳性率10%，P53(+)，EGFR(−)，E-cad(+)，P120膜(+)，SMMHC、P63示阳性缺失。术后口服托瑞米芬治疗6年余，后改为依西美坦治疗。随访99个月，无复发转移。</p><p>图1. 3例男性EPC患者乳房肿块切除标本病理诊断图(HE染色&#215;100)</p></sec><sec id="s7"><title>3. 讨论</title><p>乳腺包裹性乳头状癌是指界限清楚且局限于一囊腔内，组织学呈乳头状瘤样结构的恶性上皮性增生的一种较为少见的乳腺癌。其最初被Carter等人 [<xref ref-type="bibr" rid="hanspub.39683-ref3">3</xref>] 描述为导管内癌的一种变异类型，Hill和Yeh等 [<xref ref-type="bibr" rid="hanspub.39683-ref4">4</xref>] 研究发现肿瘤囊壁周围肌上皮细胞表达缺失，不同于导管内癌，于是提出了包裹性乳头状癌的概念。2012年WHO乳腺肿瘤病理和遗传学分类将EPC作为导管内乳头状病变的独立亚型 [<xref ref-type="bibr" rid="hanspub.39683-ref5">5</xref>]。现多认为EPC是一种低级别或呈惰性的浸润性癌，也可能是原位癌向浸润性癌过渡的一种类型，与其他类型乳腺癌相比，EPC具有明显的病理特征和较好的预后。</p><p>EPC患者首发症状常以可触及的乳房肿块就诊，可伴乳头溢液。一般病史较长，肿块大多位于乳晕下或近乳晕区，男性EPC患者的临床表现与女性相似，本组3例患者临床表现与之相符。EPC的临床表现和辅助检查缺乏特异性，易与乳腺良性病变及乳腺其他肿瘤混淆。虽然术前细针穿刺活检细胞学检查可以作为男性EPC患者的一种检测手段，但EPC细胞学检查的假阴性结果较常见 [<xref ref-type="bibr" rid="hanspub.39683-ref6">6</xref>]，其术前诊断仍依赖于术后病理和免疫组织化学检测。本组3例男性患者均通过乳房肿块切除活检得以诊断明确。必要时应对乳房肿块进行切除活检以明确诊断。</p><p>EPC的治疗尚无统一的管理指南，目前普遍的共识是进行适当的手术切除，但要保证阴性的切缘 [<xref ref-type="bibr" rid="hanspub.39683-ref7">7</xref>]。对于女性EPC患者，保乳手术和患侧乳房全切除术都可作为手术方法，男性可参照女性的手术处理原则，但由于男性乳腺组织较小，保乳手术主要针对女性。本组3例男性患者均经确诊后行患侧乳房全切除术。SEER数据库 [<xref ref-type="bibr" rid="hanspub.39683-ref8">8</xref>] 的一项大型数据分析说明了EPC患者保乳术后辅助放射治疗的益处，可为行保乳手术的EPC患者提供放射治疗。EPC呈惰性的生物学行为，进展缓慢，极少累及区域淋巴结。本组3例男性患者的术后病理显示1例为单纯EPC，1例为EPC伴浸润性癌，1例为EPC伴导管原位癌，均未有区域淋巴结累及。有研究证实，在EPC伴有浸润性癌的患者中，淋巴结转移更为常见 [<xref ref-type="bibr" rid="hanspub.39683-ref9">9</xref>]。对于伴浸润性癌的EPC患者可进行前哨淋巴结活检来评估腋窝淋巴结状态，以明确肿瘤分期，避免过度治疗。</p><p>一项对917例EPC患者的研究 [<xref ref-type="bibr" rid="hanspub.39683-ref1">1</xref>] 发现，无论何种病理状态，EPC预后都很好，局部复发和远处转移的风险较低，辅助治疗的作用尚没有明确的定义。但由于大多数EPC患者ER受体表达阳性，单纯EPC可按导管原位癌一样分期和治疗 [<xref ref-type="bibr" rid="hanspub.39683-ref10">10</xref>]，激素受体阳性的患者可行辅助内分泌治疗。对于伴浸润性癌EPC患者的治疗，应考虑浸润性癌成分。本组3例男性患者ER受体均表达阳性，HER-2均表达阴性，Ki-67低表达，术后均接受辅助内分泌治疗，无复发和远处转移。</p><p>EPC是一种局限性疾病，腋窝淋巴结和远处转移率低，男性EPC患者的治疗原则可参考女性，通过合理的手术和术后辅助治疗，患者生存率高，预后良好。</p></sec><sec id="s8"><title>同意书</title><p>该文病例报道获得病人的知情同意。</p></sec><sec id="s9"><title>文章引用</title><p>李凯迪,李文凤. 男性乳腺包裹性乳头状癌3例报道并文献复习Encapsulated Papillary Carcinoma of the Male Breast: Three Case Reports and Review of the Literature[J]. 临床医学进展, 2021, 11(01): 34-37. https://doi.org/10.12677/ACM.2021.111005</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39683-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Grabowski, J., Salzstein, S.L., Sadler, G.R., et al. (2008) Intracystic Papillary Carcinoma: A Review of 917 Cases. Cancer, 113, 916-920. &lt;br&gt;https://doi.org/10.1002/cncr.23723</mixed-citation></ref><ref id="hanspub.39683-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Yalaza, M., İnan, A. and Bozer, M. (2016) Male Breast Cancer. Journal Breast Health, 12, 1-8.  
&lt;br&gt;https://doi.org/10.5152/tjbh.2015.2711</mixed-citation></ref><ref id="hanspub.39683-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Carter, D. (1977) Intraductal Papillary Tumors of the Breast: A Study of 78 Cases. Cancer, 39, 1689-1692.  
&lt;br&gt;https://doi.org/10.1002/1097-0142(197704)39:4&lt;1689::AID-CNCR2820390444&gt;3.0.CO;2-L</mixed-citation></ref><ref id="hanspub.39683-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Hill, C.B. and Yeh, I.T. (2005) Myoepithelial Cell Staining Patterns of Papillary Breast Lesions: From Intraductal Papillomas to Invasive Papillary Carcinomas. American Journal of Clinical Pathology, 123, 36-44.  
&lt;br&gt;https://doi.org/10.1309/XG7TPQ16DMJAV8P1</mixed-citation></ref><ref id="hanspub.39683-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Frank, G.A., Danilova, N.V., Iuiu, A., et al. (2012) WHO Classification of Tumors of the Breast, 2012. Arkhiv Patologii, 75, 53-63.</mixed-citation></ref><ref id="hanspub.39683-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ko, K.H., Kim, E.K. and Park, B.W. (2006) Invasive Papillary Carcinoma of the Breast Presenting as Post-Traumatic Recurrent Hemorrhagic Cysts. Yonsei Medical Journal, 47, 575-577. &lt;br&gt;https://doi.org/10.3349/ymj.2006.47.4.575</mixed-citation></ref><ref id="hanspub.39683-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Stamatakos, M., Stefanaki, C., Stasinou, T., et al. (2011) Intracystic Papillary Carcinoma of the Breast in Males. In Search of the Optimal Treatment for this Rare Disease. Breast Care, 6, 399-403. &lt;br&gt;https://doi.org/10.1159/000331386</mixed-citation></ref><ref id="hanspub.39683-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Mogal, H., Brown, D.R., Isom, S., et al. (2016) Intracystic Papillary Carcinoma of the Breast: A SEER Database Analysis of Implications for Therapy. The Breast, 27, 87-92. &lt;br&gt;https://doi.org/10.1016/j.breast.2016.01.003</mixed-citation></ref><ref id="hanspub.39683-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Wynveen, C.A., Nehhozina, T., Akram, M., et al. (2011) Intracystic Papillary Carcinoma of the Breast: An in Situ or Invasive Tumor? Results of Immunohistochemical Analysis and Clinical Follow-Up. American Journal of Surgical Pathology, 35, 1-14. &lt;br&gt;https://doi.org/10.1097/PAS.0b013e3181fbe20a</mixed-citation></ref><ref id="hanspub.39683-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Rakha, E.A., Gandhi, N., Climent, F., et al. (2011) Encapsulated Papillary Carcinoma of the Breast: An Invasive Tumor with Excellent Prognosis. American Journal of Surgical Pathology, 35, 1093-1003.  
&lt;br&gt;https://doi.org/10.1097/PAS.0b013e31821b3f65</mixed-citation></ref></ref-list></back></article>